COMMUNIQUÉS West-GlobeNewswire

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
28/02/2025
Webcast to be held Monday, March 3rd at 8:30 a.m. ET SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel [...]
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/02/2025
REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting [...]
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
28/02/2025
Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies. The company’s ExacTcell™ technology enabled a proof-of-concept trial with highly positive results, published in Blood [...]
Groupe PAT : Hausse du Chiffre d’Affaires Combiné 2024
28/02/2025
Vandœuvre-lès-Nancy, le 28 février 2025 - 18 : 30 (CET) Communiqué de presse Pour diffusion immédiate Hausse du Chiffre d’Affaires Combiné 2024 Chiffre d’affaires combiné non audité en progression à 2,9 M€ (+26%/2023) [...]
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
28/02/2025
If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – Valneva SE (Nasdaq: [...]
Valneva reçoit un avis positif du CHMP de l’EMA pour élargir l’indication de son vaccin contre le chikungunya IXCHIQ® aux adolescents
28/02/2025
Si l’avis est validé par la Commission Européenne, IXCHIQ ® pourrait devenir le premier vaccin contre le chikungunya disponible en Europe pour les adolescents âgés de 12 ans et plus Saint Herblain (France), le 28 [...]
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older
28/02/2025
First chikungunya vaccine approved in Europe for persons as young as 12 years old. On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX [...]
Orion Corporation: Managers’ transactions – Outi Vaarala
28/02/2025
ORION CORPORATION MANAGERS’ TRANSACTIONS 28 FEBRUARY 2025 at 17.45 EET Orion Corporation: Managers’ transactions – Outi Vaarala Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) [...]
SRx Health Solutions Granted Final Order to Proceed with the Acquisition by Better Choice Company
28/02/2025
TAMPA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, announced today that SRx Health Solutions, Inc. (“ [...]
CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call
28/02/2025
DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Spectral AI, Inc. (NASDAQ: MDAI), the reporting date of the financial results for the fourth quarter was incorrectly [...]
Orion Corporation: Managers’ transactions – Niclas Lindstedt
28/02/2025
ORION CORPORATION MANAGERS’ TRANSACTIONS 28 FEBRUARY 2025 at 17.00 EET Orion Corporation: Managers’ transactions – Niclas Lindstedt Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting
28/02/2025
All resolutions were approved MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of [...]
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
28/02/2025
– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – – Additional Phase 2 e-poster presentations to [...]
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
28/02/2025
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx ® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase III REMIX pivotal [...]
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
28/02/2025
One poster will share pooled INTEGUMENT data of ZORYVE ® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical treatments [...]
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
28/02/2025
Hangzhou, China, Feb. 28, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices, through its subsidiary, Work (Hangzhou) Medical [...]
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
28/02/2025
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all [...]
Ultimovacs ASA: Approval and publication of prospectus
28/02/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
28/02/2025
Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains OCALA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today [...]

Pages